vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Vita Coco Company, Inc. (COCO). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $179.8M, roughly 1.4× Vita Coco Company, Inc.). Vita Coco Company, Inc. runs the higher net margin — 17.0% vs 11.1%, a 5.8% gap on every dollar of revenue. On growth, Vita Coco Company, Inc. posted the faster year-over-year revenue change (37.3% vs 29.6%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 11.7%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
The Vita Coco Company, doing business simply as Vita Coco, is an American beverage company which mainly sells coconut water. The largest brand globally in coconut/plant waters, Vita Coco has operations in 31 countries as of 2016. It is a benefit corporation. The company is owned by All Market Inc.
ANIP vs COCO — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $179.8M |
| Net Profit | $27.5M | $30.5M |
| Gross Margin | — | 39.9% |
| Operating Margin | 14.1% | 18.7% |
| Net Margin | 11.1% | 17.0% |
| Revenue YoY | 29.6% | 37.3% |
| Net Profit YoY | 367.5% | 61.4% |
| EPS (diluted) | $1.14 | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $179.8M | ||
| Q4 25 | $247.1M | $127.8M | ||
| Q3 25 | $227.8M | $182.3M | ||
| Q2 25 | $211.4M | $168.8M | ||
| Q1 25 | $197.1M | $130.9M | ||
| Q4 24 | $190.6M | $127.3M | ||
| Q3 24 | $148.3M | $132.9M | ||
| Q2 24 | $138.0M | $144.1M |
| Q1 26 | — | $30.5M | ||
| Q4 25 | $27.5M | $5.5M | ||
| Q3 25 | $26.6M | $24.0M | ||
| Q2 25 | $8.5M | $22.9M | ||
| Q1 25 | $15.7M | $18.9M | ||
| Q4 24 | $-10.3M | $3.4M | ||
| Q3 24 | $-24.2M | $19.3M | ||
| Q2 24 | $-2.3M | $19.1M |
| Q1 26 | — | 39.9% | ||
| Q4 25 | — | 34.9% | ||
| Q3 25 | — | 37.7% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 36.7% | ||
| Q4 24 | — | 32.5% | ||
| Q3 24 | — | 38.8% | ||
| Q2 24 | — | 40.8% |
| Q1 26 | — | 18.7% | ||
| Q4 25 | 14.1% | 8.0% | ||
| Q3 25 | 15.9% | 15.3% | ||
| Q2 25 | 6.6% | 14.9% | ||
| Q1 25 | 13.3% | 14.7% | ||
| Q4 24 | -2.3% | 3.4% | ||
| Q3 24 | -13.8% | 15.5% | ||
| Q2 24 | 3.7% | 20.8% |
| Q1 26 | — | 17.0% | ||
| Q4 25 | 11.1% | 4.3% | ||
| Q3 25 | 11.7% | 13.2% | ||
| Q2 25 | 4.0% | 13.6% | ||
| Q1 25 | 8.0% | 14.4% | ||
| Q4 24 | -5.4% | 2.6% | ||
| Q3 24 | -16.3% | 14.5% | ||
| Q2 24 | -1.7% | 13.2% |
| Q1 26 | — | $0.50 | ||
| Q4 25 | $1.14 | $0.10 | ||
| Q3 25 | $1.13 | $0.40 | ||
| Q2 25 | $0.36 | $0.38 | ||
| Q1 25 | $0.69 | $0.31 | ||
| Q4 24 | $-0.45 | $0.06 | ||
| Q3 24 | $-1.27 | $0.32 | ||
| Q2 24 | $-0.14 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $201.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $352.2M |
| Total Assets | $1.4B | $488.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $201.9M | ||
| Q4 25 | $285.6M | $196.9M | ||
| Q3 25 | $262.6M | $203.7M | ||
| Q2 25 | $217.8M | $167.0M | ||
| Q1 25 | $149.8M | $153.6M | ||
| Q4 24 | $144.9M | $164.7M | ||
| Q3 24 | $145.0M | $156.7M | ||
| Q2 24 | $240.1M | $150.1M |
| Q1 26 | — | $352.2M | ||
| Q4 25 | $540.7M | $331.5M | ||
| Q3 25 | $505.8M | $323.7M | ||
| Q2 25 | $436.8M | $296.9M | ||
| Q1 25 | $418.6M | $277.9M | ||
| Q4 24 | $403.7M | $258.8M | ||
| Q3 24 | $405.9M | $252.1M | ||
| Q2 24 | $455.8M | $232.0M |
| Q1 26 | — | $488.3M | ||
| Q4 25 | $1.4B | $461.2M | ||
| Q3 25 | $1.4B | $461.3M | ||
| Q2 25 | $1.3B | $421.1M | ||
| Q1 25 | $1.3B | $384.0M | ||
| Q4 24 | $1.3B | $362.4M | ||
| Q3 24 | $1.3B | $353.1M | ||
| Q2 24 | $920.8M | $323.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $-3.9M | ||
| Q3 25 | $44.1M | $39.1M | ||
| Q2 25 | $75.8M | $21.8M | ||
| Q1 25 | $35.0M | $-9.8M | ||
| Q4 24 | $15.9M | $6.9M | ||
| Q3 24 | $12.5M | $9.3M | ||
| Q2 24 | $17.4M | $26.9M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $-7.1M | ||
| Q3 25 | $38.0M | $35.6M | ||
| Q2 25 | $71.8M | $20.9M | ||
| Q1 25 | $32.5M | $-10.4M | ||
| Q4 24 | $13.5M | $6.8M | ||
| Q3 24 | $7.7M | $8.9M | ||
| Q2 24 | $13.0M | $26.6M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | -5.6% | ||
| Q3 25 | 16.7% | 19.6% | ||
| Q2 25 | 34.0% | 12.4% | ||
| Q1 25 | 16.5% | -7.9% | ||
| Q4 24 | 7.1% | 5.3% | ||
| Q3 24 | 5.2% | 6.7% | ||
| Q2 24 | 9.4% | 18.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 2.5% | ||
| Q3 25 | 2.7% | 1.9% | ||
| Q2 25 | 1.9% | 0.6% | ||
| Q1 25 | 1.3% | 0.4% | ||
| Q4 24 | 1.3% | 0.1% | ||
| Q3 24 | 3.2% | 0.3% | ||
| Q2 24 | 3.2% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | -0.70× | ||
| Q3 25 | 1.66× | 1.63× | ||
| Q2 25 | 8.87× | 0.95× | ||
| Q1 25 | 2.23× | -0.52× | ||
| Q4 24 | — | 2.05× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 1.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
COCO
| Subtotal | $148.2M | 82% |
| Private Label | $24.4M | 14% |
| Other | $7.2M | 4% |
